HOXB9 promotes osteosarcoma cell survival and malignancy under glucose starvation via upregulating SPP1 expression
In this study, we found that HOXB9 was increased upon glucose starvation. Elevated HOXB9 suppressed osteosarcoma cell death and supported cell growth and migration under glucose starvation. Further mechanistic studies demonstrated that HOXB9 directly bound to the promoter of secreted phosphoprotein 1 (SPP1) and transcriptionally upregulated SPP1 expression which then led cell death decrease and cell growth increase under glucose deprivation environment. Clinically, HOXB9 was significantly upregulated in osteosarcoma compared with normal tissues and increase of HOXB9 expression was positively associated with the elevation o...
Source: Biochemical Pharmacology - April 15, 2024 Category: Drugs & Pharmacology Authors: Jian Han Renchen Ji Shuo Zheng Xin Xia Wenxiao Du Hongtao He Chuanchun Han Wenzhi Zhao Xiaojie Li Yuan Wang Lu Zhang Source Type: research
A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
In conclusion, we provide a useful model for exploring the chronological ALD-associated alterations and stages, and addressing therapeutic approaches.PMID:38621424 | DOI:10.1016/j.bcp.2024.116209 (Source: Biochemical Pharmacology)
Source: Biochemical Pharmacology - April 15, 2024 Category: Drugs & Pharmacology Authors: Brisa Rodope Alarc ón-Sánchez Osiris Germ án Idelfonso-García Dafne Guerrero-Escalera Carolina Pi ña-Vázquez Guillermo de Anda-J áuregui Jos é Luis Pérez-Hernández Mireya de la Garza Francisco Garc ía-Sierra Yesennia S ánchez-Pérez Rafael Bal Source Type: research
Tanshinone IIA acts as a regulator of lipogenesis to overcome osimertinib acquired resistance in lung cancer
Biochem Pharmacol. 2024 Apr 13:116207. doi: 10.1016/j.bcp.2024.116207. Online ahead of print.ABSTRACTOsimertinib is a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), acting as the first-line medicine for advanced EGFR-mutated NSCLC. Recently, the acquired resistance to osimertinib brings great challenges to the advanced treatment. Therefore, it is in urgent need to find effective strategy to overcome osimertinib acquired resistance. Here, we demonstrated that SREBP pathway-driven lipogenesis was a key mediator to promote osimertinib acquired resistance, and firstly found Tanshinone IIA (Tan IIA...
Source: Biochemical Pharmacology - April 15, 2024 Category: Drugs & Pharmacology Authors: Lin Cao Zhiyan Qin Ting Yu Xupeng Bai Shiqin Jiang Daifei Wang Fangqing Ning Min Huang Jing Jin Source Type: research
HOXB9 promotes osteosarcoma cell survival and malignancy under glucose starvation via upregulating SPP1 expression
In this study, we found that HOXB9 was increased upon glucose starvation. Elevated HOXB9 suppressed osteosarcoma cell death and supported cell growth and migration under glucose starvation. Further mechanistic studies demonstrated that HOXB9 directly bound to the promoter of secreted phosphoprotein 1 (SPP1) and transcriptionally upregulated SPP1 expression which then led cell death decrease and cell growth increase under glucose deprivation environment. Clinically, HOXB9 was significantly upregulated in osteosarcoma compared with normal tissues and increase of HOXB9 expression was positively associated with the elevation o...
Source: Biochemical Pharmacology - April 15, 2024 Category: Drugs & Pharmacology Authors: Jian Han Renchen Ji Shuo Zheng Xin Xia Wenxiao Du Hongtao He Chuanchun Han Wenzhi Zhao Xiaojie Li Yuan Wang Lu Zhang Source Type: research
A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
In conclusion, we provide a useful model for exploring the chronological ALD-associated alterations and stages, and addressing therapeutic approaches.PMID:38621424 | DOI:10.1016/j.bcp.2024.116209 (Source: Biochemical Pharmacology)
Source: Biochemical Pharmacology - April 15, 2024 Category: Drugs & Pharmacology Authors: Brisa Rodope Alarc ón-Sánchez Osiris Germ án Idelfonso-García Dafne Guerrero-Escalera Carolina Pi ña-Vázquez Guillermo de Anda-J áuregui Jos é Luis Pérez-Hernández Mireya de la Garza Francisco Garc ía-Sierra Yesennia S ánchez-Pérez Rafael Bal Source Type: research
Tanshinone IIA acts as a regulator of lipogenesis to overcome osimertinib acquired resistance in lung cancer
Biochem Pharmacol. 2024 Apr 13:116207. doi: 10.1016/j.bcp.2024.116207. Online ahead of print.ABSTRACTOsimertinib is a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), acting as the first-line medicine for advanced EGFR-mutated NSCLC. Recently, the acquired resistance to osimertinib brings great challenges to the advanced treatment. Therefore, it is in urgent need to find effective strategy to overcome osimertinib acquired resistance. Here, we demonstrated that SREBP pathway-driven lipogenesis was a key mediator to promote osimertinib acquired resistance, and firstly found Tanshinone IIA (Tan IIA...
Source: Biochemical Pharmacology - April 15, 2024 Category: Drugs & Pharmacology Authors: Lin Cao Zhiyan Qin Ting Yu Xupeng Bai Shiqin Jiang Daifei Wang Fangqing Ning Min Huang Jing Jin Source Type: research
HOXB9 promotes osteosarcoma cell survival and malignancy under glucose starvation via upregulating SPP1 expression
In this study, we found that HOXB9 was increased upon glucose starvation. Elevated HOXB9 suppressed osteosarcoma cell death and supported cell growth and migration under glucose starvation. Further mechanistic studies demonstrated that HOXB9 directly bound to the promoter of secreted phosphoprotein 1 (SPP1) and transcriptionally upregulated SPP1 expression which then led cell death decrease and cell growth increase under glucose deprivation environment. Clinically, HOXB9 was significantly upregulated in osteosarcoma compared with normal tissues and increase of HOXB9 expression was positively associated with the elevation o...
Source: Biochemical Pharmacology - April 15, 2024 Category: Drugs & Pharmacology Authors: Jian Han Renchen Ji Shuo Zheng Xin Xia Wenxiao Du Hongtao He Chuanchun Han Wenzhi Zhao Xiaojie Li Yuan Wang Lu Zhang Source Type: research
A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
In conclusion, we provide a useful model for exploring the chronological ALD-associated alterations and stages, and addressing therapeutic approaches.PMID:38621424 | DOI:10.1016/j.bcp.2024.116209 (Source: Biochemical Pharmacology)
Source: Biochemical Pharmacology - April 15, 2024 Category: Drugs & Pharmacology Authors: Brisa Rodope Alarc ón-Sánchez Osiris Germ án Idelfonso-García Dafne Guerrero-Escalera Carolina Pi ña-Vázquez Guillermo de Anda-J áuregui Jos é Luis Pérez-Hernández Mireya de la Garza Francisco Garc ía-Sierra Yesennia S ánchez-Pérez Rafael Bal Source Type: research
Tanshinone IIA acts as a regulator of lipogenesis to overcome osimertinib acquired resistance in lung cancer
Biochem Pharmacol. 2024 Apr 13:116207. doi: 10.1016/j.bcp.2024.116207. Online ahead of print.ABSTRACTOsimertinib is a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), acting as the first-line medicine for advanced EGFR-mutated NSCLC. Recently, the acquired resistance to osimertinib brings great challenges to the advanced treatment. Therefore, it is in urgent need to find effective strategy to overcome osimertinib acquired resistance. Here, we demonstrated that SREBP pathway-driven lipogenesis was a key mediator to promote osimertinib acquired resistance, and firstly found Tanshinone IIA (Tan IIA...
Source: Biochemical Pharmacology - April 15, 2024 Category: Drugs & Pharmacology Authors: Lin Cao Zhiyan Qin Ting Yu Xupeng Bai Shiqin Jiang Daifei Wang Fangqing Ning Min Huang Jing Jin Source Type: research
Isobavachin attenuates osteoclastogenesis and periodontitis-induced bone loss by inhibiting cellular iron accumulation and mitochondrial biogenesis
Biochem Pharmacol. 2024 Apr 12:116202. doi: 10.1016/j.bcp.2024.116202. Online ahead of print.ABSTRACTAs bone-resorbing cells rich in mitochondria, osteoclasts require high iron uptake to promote mitochondrial biogenesis and maintain a high-energy metabolic state for active bone resorption. Given that abnormal osteoclast formation and activation leads to imbalanced bone remodeling and osteolytic bone loss, osteoclasts may be crucial targets for treating osteolytic diseases such as periodontitis. Isobavachin (IBA), a natural flavonoid compound, has been confirmed to be an inhibitor of receptor activator of nuclear factor κB...
Source: Biochemical Pharmacology - April 14, 2024 Category: Drugs & Pharmacology Authors: Ting Li Yangge Du Hantao Yao Boxuan Zhao Zijun Wang Rourong Chen Yaoting Ji Minquan Du Source Type: research
The antiprotozoal drug nitazoxanide improves experimental liver fibrosis in mice
In conclusion, nitazoxanide inhibits liver fibrosis and the underlying mechanisms involve AMPK activation, and STAT3 and Smad2/3 inhibition.PMID:38615918 | DOI:10.1016/j.bcp.2024.116205 (Source: Biochemical Pharmacology)
Source: Biochemical Pharmacology - April 14, 2024 Category: Drugs & Pharmacology Authors: Kai-Xin Liu Zeng-Yang Wang Ya-Ting Ying Rui-Miao Wei De-Li Dong Zhi-Jie Sun Source Type: research
Butyrate promotes kidney resilience through a coordinated kidney protective response in tubular cells
In conclusion, butyrate promotes kidney resilience to AKI and decreases inflammation by preventing the downregulation of kidney protective genes such as Klotho. This information may be relevant to optimize antibiotic management during hospitalization.PMID:38615919 | DOI:10.1016/j.bcp.2024.116203 (Source: Biochemical Pharmacology)
Source: Biochemical Pharmacology - April 14, 2024 Category: Drugs & Pharmacology Authors: Chiara Favero Aranzazu Pintor-Chocano Ana Sanz Alberto Ortiz Maria D Sanchez-Ni ño Source Type: research
CaMK4: Structure, physiological functions, and therapeutic potential
Biochem Pharmacol. 2024 Apr 12:116204. doi: 10.1016/j.bcp.2024.116204. Online ahead of print.ABSTRACTCalcium/calmodulin-dependent protein kinase IV (CaMK4) is a versatile serine/threonine kinase involved in various cellular functions. It regulates T-cell differentiation, podocyte function, tumor cell proliferation/apoptosis, β cell mass, and insulin sensitivity. However, the underlying molecular mechanisms are complex and remain incompletely understood. The aims of this review are to highlight the latest advances in the regulatory mechanisms of CaMK4 underlying T-cell imbalance and parenchymal cell mass in multiple diseas...
Source: Biochemical Pharmacology - April 14, 2024 Category: Drugs & Pharmacology Authors: Hao Xu Liang Yong Xianxian Gao Yandong Chen Yixuan Wang Fuyan Wang Xin Hou Source Type: research
ACSL4 promotes malignant progression of Hepatocellular carcinoma by targeting PAK2 transcription
Biochem Pharmacol. 2024 Apr 12:116206. doi: 10.1016/j.bcp.2024.116206. Online ahead of print.ABSTRACTLong-chain fatty acyl-Coa ligase 4 (ACSL4) is an important enzyme that converts fatty acids to fatty acyl-Coa esters, there is increasing evidence for its role in carcinogenesis. However, the precise role of ACLS4 in hepatocellular carcinoma (HCC) is not clearly understood. In the present study, we provide evidence that ACSL4 expression was specifically elevated in HCC and is associated with poor clinical outcomes. ACSL4 significantly promotes the growth and metastasis of HCC both in vitro and in vivo. RNA sequencing and fu...
Source: Biochemical Pharmacology - April 14, 2024 Category: Drugs & Pharmacology Authors: Dandan Wu Zongchao Zuo Xinning Sun Xin Li Fangzhou Yin Wu Yin Source Type: research
Isobavachin attenuates osteoclastogenesis and periodontitis-induced bone loss by inhibiting cellular iron accumulation and mitochondrial biogenesis
Biochem Pharmacol. 2024 Apr 12:116202. doi: 10.1016/j.bcp.2024.116202. Online ahead of print.ABSTRACTAs bone-resorbing cells rich in mitochondria, osteoclasts require high iron uptake to promote mitochondrial biogenesis and maintain a high-energy metabolic state for active bone resorption. Given that abnormal osteoclast formation and activation leads to imbalanced bone remodeling and osteolytic bone loss, osteoclasts may be crucial targets for treating osteolytic diseases such as periodontitis. Isobavachin (IBA), a natural flavonoid compound, has been confirmed to be an inhibitor of receptor activator of nuclear factor κB...
Source: Biochemical Pharmacology - April 14, 2024 Category: Drugs & Pharmacology Authors: Ting Li Yangge Du Hantao Yao Boxuan Zhao Zijun Wang Rourong Chen Yaoting Ji Minquan Du Source Type: research
